TY - JOUR
T1 - Pathogenesis of psoriasis in the “omic” era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances
AU - Samotij, Dominik
AU - Nedoszytko, Bogusław
AU - Bartosińska, Joanna
AU - Batycka-Baran, Aleksandra
AU - Czajkowski, Rafał
AU - Dobrucki, Iwona T.
AU - Dobrucki, Lawrence W.
AU - Górecka-Sokołowska, Magdalena
AU - Janaszak-Jasienicka, Anna
AU - Krasowska, Dorota
AU - Kalinowski, Leszek
AU - Macieja-Stawczyk, Marta
AU - Nowicki, Roman J.
AU - Owczarczyk-Saczonek, Agnieszka
AU - Płoska, Agata
AU - Purzycka-Bohdan, Dorota
AU - Radulska, Adrianna
AU - Reszka, Edyta
AU - Siekierzycka, Anna
AU - Słomiński, Andrzej
AU - Słomiński, Radomir
AU - Sobalska-Kwapis, Marta
AU - Strapagiel, Dominik
AU - Szczerkowska-Dobosz, Aneta
AU - Szczęch, Justyna
AU - Żmijewski, Michał
AU - Reich, Adam
N1 - Publisher Copyright:
© 2020 Termedia Publishing House Ltd.. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Psoriasis is a common, chronic, inflammatory, immune-mediated skin disease affecting about 2% of the world’s population. According to current knowledge, psoriasis is a complex disease that involves various genes and environmental factors, such as stress, injuries, infections and certain medications. The chronic inflammation of psoriasis lesions develops upon epidermal infiltration, activation, and expansion of type 1 and type 17 Th cells. Despite the enormous progress in understanding the mechanisms that cause psoriasis, the target cells and antigens that drive pathogenic T cell responses in psoriatic lesions are still unproven and the autoimmune basis of psoriasis still remains hypothetical. However, since the identification of the Th17 cell subset, the IL-23/Th17 immune axis has been considered a key driver of psoriatic inflammation, which has led to the development of biologic agents that target crucial elements of this pathway. Here we present the current understanding of various aspects in psoriasis pathogenesis.
AB - Psoriasis is a common, chronic, inflammatory, immune-mediated skin disease affecting about 2% of the world’s population. According to current knowledge, psoriasis is a complex disease that involves various genes and environmental factors, such as stress, injuries, infections and certain medications. The chronic inflammation of psoriasis lesions develops upon epidermal infiltration, activation, and expansion of type 1 and type 17 Th cells. Despite the enormous progress in understanding the mechanisms that cause psoriasis, the target cells and antigens that drive pathogenic T cell responses in psoriatic lesions are still unproven and the autoimmune basis of psoriasis still remains hypothetical. However, since the identification of the Th17 cell subset, the IL-23/Th17 immune axis has been considered a key driver of psoriatic inflammation, which has led to the development of biologic agents that target crucial elements of this pathway. Here we present the current understanding of various aspects in psoriasis pathogenesis.
KW - Autoimmunity
KW - Interleukins
KW - Neoangiogenesis
KW - Neurogenic inflammation
KW - Psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85086930552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086930552&partnerID=8YFLogxK
U2 - 10.5114/ada.2020.94832
DO - 10.5114/ada.2020.94832
M3 - Review article
C2 - 32489346
AN - SCOPUS:85086930552
SN - 1642-395X
VL - 37
SP - 135
EP - 153
JO - Postepy Dermatologii I Alergologii
JF - Postepy Dermatologii I Alergologii
IS - 2
ER -